The approved product is a generic version of Lotemax SM ophthalmic gel, 0.38%, originally developed by Bausch & Lomb Inc. Shares of Lupin Ltd ended at ₹1,968, up by ₹30.20, or 1.56%, on the BSE.
The approved product is a generic version of Lotemax SM ophthalmic gel, 0.38%, originally developed by Bausch & Lomb Inc. Shares of Lupin Ltd ended at ₹1,968, up by ₹30.20, or 1.56%, on the BSE.